19 results about "Tos ferina" patented technology

The invention relates to the technical field of biology, in particular to a primer probe combination product for respiratory tract infection detection. A plurality of specific primers and self-quenching probes are integrated in a single reaction system; simultaneous, rapid and rapid detection on 15 respiratory pathogens (including influenza A virus, influenza B virus, respiratory syncytial virus, severe acute respiratory syndrome coronavirus 2, mycoplasma pneumoniae, parainfluenza virus, rhinovirus, enterovirus, coronavirus, adenovirus, metapneumovirus, bordetella pertussis, bocavirus, chlamydia pneumoniae and chlamydia psittaci) is realized. The detection is accurate.

The invention discloses a reagent combination and a kit for detecting four respiratory tract pathogens based on qPCR, and belongs to the technical field of microbiological detection. Wherein the four respiratory tract pathogens are respectively human adenovirus, human bocavirus, bordetella pertussis and mycoplasma pneumoniae; the kit also comprises an optimized PCR (Polymerase Chain Reaction) buffer solution, DNA (Deoxyribose Nucleic Acid) polymerase and UDG enzyme. Through screening processes such as specific primer probe design, reagent formula and reaction system optimization, high sensitivity and high specificity are maintained while rapid detection is performed, and missing detection and misjudgment are effectively avoided.

The invention provides a primer for detecting bordetella pertussis through RPA (recombinase polymerase amplification)-lateral flow immunochromatography. The primer comprises specific primer pairs NAT-F and NAT-R which are designed aiming at transposase genes of a bordetella pertussis IS1663 family, and specific primer pairs NAT-F and NAT-R which are designed aiming at transposase genes of a bordetella pertussis IS1663 family, the invention also provides corresponding probes, which comprise a gold nanoparticle binding probe, a quality control line capture probe and a bordetella pertussis IS1663 capture probe. Meanwhile, the invention further provides application of the primer and the probe in preparation of a pertussis bordetella detection product, a specific detection kit and a specific detection method. According to the invention, the specific primer and probe are designed aiming at the transposase gene of the pertussis bordetella IS110-like element IS1663 family, and the rapid, high-sensitivity and high-specificity detection of pertussis bordetella is realized by fusing the rapid isothermal amplification technology of RPA and the visual detection advantage of lateral flow immunochromatography, no complex instrument or professional operation is needed, and the kit has the advantages of high sensitivity, high specificity, high sensitivity and high specificity. The method is suitable for multi-scene early convenient diagnosis.

The present application belongs to the field of molecular biology detection, and particularly relates to detection of pathogenic bacteria related to respiratory tract infection, and more particularly to detection of Bordetella parapertussis, Bordetella hockingense and Bordetella bronchiseptica. The composition for combined detection provided by the present application mainly utilizes a multiplex fluorescence PCR analysis method, and different pathogenic bacteria are detected by detecting target points on different pathogenic bacteria, so that detection and differentiation of Bordetella parapertussis, Bordetella hockingense and Bordetella bronchiseptica are simultaneously achieved in a single tube reaction system. The composition of the present application has higher sensitivity, reaches 500 copies / mL, has good specificity, and is more accurate in detection.

The present disclosure relates to the technical field of medicine, and in particular to a pharmaceutical composition, preparation method and use thereof. The pharmaceutical composition includes a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient. The first active ingredient is a microbial agent, including one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, and Salmonella paratyphi. The second active ingredient includes polyinosinic acid, polycytidylic acid, and vitamin. The pharmaceutical composition of the present disclosure pertains to an artificial active immunotherapy for tumors. It can “stimulate” the entire immune system, making the therapy of using bacteria to activate the human immune system to kill cancer cells highly stable and reliable. This composition can significantly save and prolong the lives of cancer patients while exhibiting extremely high safety, minimal toxic side effects, and low production costs.

The invention discloses a method for preparing pertussis component antigens PT and FHA by adopting one-step chromatography, and particularly, the method comprises the following steps: (1) after pertussis thalli are fermented, harvesting supernatant and concentrating to obtain a fermented supernatant concentrated solution; (2) regulating the conductivity and pH value of the fermentation supernatant concentrated solution, and then performing chromatographic purification by adopting a multi-mode weak cation exchange medium, wherein the chromatographic purification comprises the steps of eluting by adopting a first eluent to obtain FHA and eluting by adopting a second eluent to obtain PT; wherein the conductivity of the adjusted fermented supernatant concentrate in the step (2) is less than or equal to 10mS / cm, and the pH value is 6-7.5; the first eluent is a phosphate buffer solution with the pH value of 6-7 and containing 0.12 M-0. 2M of sodium chloride, and the second eluent is a buffer solution with the pH value of 8.5-9.6 and containing 0M of sodium chloride.

The invention discloses a composition, a kit and a detection method for detecting pulmonary infection pathogens. The composition comprises at least one of a component A, a component B, a component C and a component D, the component A comprises a primer pair SEQ ID NO: 1-2 and a probe SEQ ID NO: 3; detecting bordetella pertussis by the component A; the component B comprises a primer pair SEQ ID NO: 4-5 and a probe SEQ ID NO: 6; the component B is used for detecting Nocardia; the component C comprises a primer pair SEQ ID NO: 7-8 and a probe SEQ ID NO: 9; detecting cryptococcus neoformans by the component C; the component D comprises a primer pair SEQ ID NO: 10 to 11 and a probe SEQ ID NO: 12; the component D is used for detecting acinetobacter baumannii. The composition for detecting the pulmonary infection pathogens provided by the invention can detect and distinguish at least one of bordetella pertussis, nocardia, cryptococcus neoformans and acinetobacter baumannii, has higher sensitivity, specificity and precision, can accurately and quickly detect bordetella pertussis, nocardia, cryptococcus neoformans and acinetobacter baumannii, and can be used for detecting the pulmonary infection pathogens. The detection efficiency is improved, the detection period is shortened, and detection is convenient.

Disclosed in the present invention is a compound adjuvant combined vaccine, comprising an immunogenic composition and a compound adjuvant. The immunogenic composition comprises a pertussis antigen, a diphtheria antigen and a tetanus antigen; and the compound adjuvant is composed of an aluminum adjuvant and a TLR9 receptor agonist. Further disclosed in the present invention is a use of the compound adjuvant in the preparation of the compound adjuvant combined vaccine for preventing pertussis, diphtheria and tetanus in a subject.

The invention belongs to the technical field of biological medicines and vaccines, and particularly relates to a pertussis Bordetella mRNA (messenger Ribonucleic Acid) vaccine and application thereof. Specifically, the bordetella pertussis mRNA vaccine capable of inducing an organism to generate TH1 immune bias is successfully prepared, three antigens (pertussis toxin, filamentous hemagglutinin and pertussis adhesion) of pertussis are coded by mRNA based on the immune response advantage of the mRNA vaccine, so that the organism can be stimulated to generate good TH1 / TH17 immune response, and the immune response of the organism is enhanced. And thus, colonization and removal of the respiratory tract of the pertussis bacteria are realized, and finally, the protective efficacy of the vaccine is greatly improved, so that the method has good practical application value.

The invention relates to the technical field of biological detection, and discloses a composition for detecting respiratory tract infection pathogens, a kit and application. The composition disclosed by the invention can be used for rapidly and simultaneously detecting legionella pneumophila, bordetella pertussis, chlamydia pneumoniae, mycoplasma pneumoniae, mycobacterium tuberculosis, aspergillus and cryptococcus neoformans in a sample with high specificity, and has relatively high sensitivity and stability. Compared with traditional detection methods such as pathogen isolated culture and genome sequencing, the efficiency of identifying and jointly detecting multiple respiratory tract pathogens by adopting the composition disclosed by the invention is effectively improved, the detection process is simple and convenient to operate, and the composition is suitable for large-scale popularization and application.

The present invention discloses a pharmaceutical composition, its manufacturing method, and its use, wherein the pharmaceutical composition comprises a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient, the first active ingredient being a microbial agent containing one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, or Salmonella paratyphi, and the second active ingredient comprising polyinosinic acid, polycytidylic acid, and vitamins. The pharmaceutical composition is an artificial active immunotherapy for tumors, which, by "stimulating" the entire immune system, activates the human immune system using bacteria to kill cancer cells, making the treatment extremely stable and reliable, significantly saving and extending the lives of cancer patients, while simultaneously being extremely safe, having very few toxic side effects, and having low manufacturing costs.

The invention discloses a monoclonal antibody aiming at a bordetella pertussis antibody as well as a preparation method and application of the monoclonal antibody. The monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 of which the sequences are respectively shown as SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 of which the sequences are respectively shown as SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. The monoclonal antibody can be used as a bordetella pertussis quality control antibody, is applied to the clinical diagnosis of pertussis, and provides reference for the clinical diagnosis of pertussis.

The application discloses a recombinant attenuated Bordetella pertussis strain and a construction method and application thereof, and belongs to the technical field of microbial genetic engineering. The application provides a recombinant attenuated Bordetella pertussis strain, and the gene detoxified pertussis toxin expressed by the recombinant strain is 10 6 times lower in toxicity than the wild type, and the gene detoxified pertussis toxin derived from the CS strain of Bordetella pertussis is proved to have good protectivity in a mouse challenge experiment for the first time, and can be used for preparing products for treating or / and detecting or / and preventing the pertussis disease, and has a good application prospect.

The invention belongs to the technical field of biological detection, and particularly relates to a sample treating fluid for detecting bordetella pertussis, a detection method, a product and application. The sample treatment liquid comprises a lysis working solution (WLB) and a post-treatment diluent (PD), the WLB is composed of choline tartrate, betaine, glycerin, TCEP, IGEPAL CA-630, HEPES and non-enzyme deionized water, and the PD is composed of bovine serum albumin and non-enzyme deionized water. The kit is suitable for common clinical samples such as sputum and nasopharynx swab eluent, bordetella pertussis can be efficiently split, target nucleic acid is fully released, and meanwhile matrix inhibitors such as mucoprotein, heme and protease in the samples are effectively removed. The kit is simple and convenient to operate, free of complex purification steps, high in detection sensitivity, good in reproducibility, high in specificity and free of cross reaction, and provides reliable technical support for early precise diagnosis and epidemic prevention and control of pertussis.

The present invention relates to vaccines and vaccine compositions, in particular vaccines and vaccine compositions inactivated with antibiotics or antibacterial compounds. In particular, the invention extends to a bacterial vaccine or vaccine composition wherein the bacteria has been inactivated by an antibiotic or an antibacterial compound. The invention further extends to the use of the vaccine and vaccine compositions as a therapeutic or as part of a vaccine in the prevention of infection with a bacterial infection, such as Bordetella pertussis, and the treatment and / or prophylaxis of bacterial diseases, such as pertussis disease (whooping cough).

The present invention relates to culture media and methods for cultivating Bordetella bacteria, particularly for producing vaccines. In particular, the inventors investigated the effects of temperature and alkaline earth metals and transition metals compositions on the growth and virulence factor production of B. pertussis and B. bronchiseptica. They found that both bacteria grew better and expressed more antigens when cultured in MILNEZ medium at 35°C, which mimics the nasal environment of healthy individuals. They also showed that B. pertussis genes were differentially regulated by these conditions. Therefore, the present invention provides a new culture medium that mimics growth conditions in the nose. The new medium includes a source of carbon, nitrogen, salts, alkaline earth metals and specific transitions metals at concentrations close to those in mammalian nasal fluid cavity. The invention aims to improve the growth of Bordetella bacteria for vaccine production.

The invention belongs to the field of biomedical treatment, and particularly relates to a convective amplification primer pair and probe for respiratory tract pathogenic bacteria and multiple detection application of the convective amplification primer pair and probe. The convection amplification primer pair comprises a legionella pneumophila primer pair, a mycoplasma pneumoniae primer pair and a bordetella pertussis primer pair, and the legionella pneumophila primer pair, the mycoplasma pneumoniae primer pair and the bordetella pertussis primer pair are respectively composed of an upstream primer and a downstream primer; each of the upstream primer and the downstream primer comprises a target nucleic acid complementary sequence and an interface sequence, and the interface sequence is located at the 5'end of the target nucleic acid complementary sequence and is not complementary with target nucleic acid; the target nucleic acid complementary sequence has a folded sequence, and the folded sequence is complementary with the interface sequence, so that the primer sequence has a curved hairpin structure, a probe is designed, and a respiratory tract pathogenic bacteria multiple detection kit is prepared. The multiple detection can avoid non-specific amplification and improve the detection sensitivity.

This invention relates to a traditional Chinese medicine composition for treating spasmodic cough in children. The composition is made from the following raw materials in parts by weight: honeysuckle 10-14 parts, earthworm 7-11 parts, cicada slough 4-8 parts, belamcanda chinensis 7-11 parts, scutellaria baicalensis 7-11 parts, honey-processed coltsfoot flower 7-11 parts, lily bulb 7-11 parts, ginger-processed bamboo shavings 7-11 parts, and licorice root 1-5 parts. This invention also provides the application of this traditional Chinese medicine composition in the preparation of a drug for treating spasmodic cough in children. In this formula, honeysuckle and earthworm are the principal herbs; cicada slough, scutellaria baicalensis, and belamcanda chinensis are the assistant herbs; ginger-processed bamboo shavings, coltsfoot flower, and lily bulb are the adjuvant herbs; and licorice root is the guiding herb. This formula treats cough with phlegm belonging to the wind-cold transforming into heat type. This invention promotes lung function, eliminates phlegm, relieves spasms, and stops cough. Main indications: spasmodic cough caused by pertussis, bronchitis, asthma, etc.

The present application relates to the technical field of biological detection, and particularly relates to a Bordetella pertussis nucleic acid detection kit. The present application uses ptxP alone or in combination with IS481 to determine Bordetella pertussis, and there is no cross reaction with pathogenic bacteria causing similar symptoms of pertussis. Meanwhile, the kit has the advantages of high sensitivity and strong specificity, and the detection can be completed in only 50 min, and the minimum detection limit can reach 1 CFU / mL. The kit is suitable for disease screening and clinical diagnosis, can greatly shorten the detection time, improve the detection efficiency, and avoid false positive results, and has important significance in disease monitoring, disease screening, clinical diagnosis and symptomatic treatment.